-- BioShield Technologies Receives Extended Patent Approval From U.S. Patent Office --
/FROM PR NEWSWIRE ATLANTA 404-231-1814/
TO BUSINESS, MEDICAL AND TECHNOLOGY EDITORS:
BioShield Technologies Receives Extended Patent Approval From U.S. Patent
Office on BioShield's AM500 Antimicrobial; Secures a Broader Array of Claims
And Potential Applications
ATLANTA, Sept. 12 /PRNewswire-FirstCall/ --
BioShield Technologies, Inc. (OTC Bulletin Board: BSTI) announces today that
it has recently received from the U.S. Patent Office an approval extending
BioShield's AM500 antimicrobial, securing the rights to a broader array of
applications and formularies. This new patent approval helps to solidify
BioShield's positioning in the coatings industry and various other industries
to control the growth of bacteria, mold, mildew and algae for both indoor or
outdoor applications. The final patent filing and respective claims are
anticipated to be issued as a U.S. Registered Patent within the next few
months.
Deirdre Baker, BioShield's General Manager stated, "this new Patent
approval contributes a great deal to our competitive advantage, creates new
barriers to entry for our competition to participate in the antimicrobial and
antibacterial industries, and further enhances and protects BioShield's
intellectual property portfolio. The approval of this Patent further
solidifies BioShield's position in the antimicrobial industry as having one of
the broadest product lines that provide the benefit of being essentially non-
toxic, water-based, non-leaching and having long-term effectiveness. Over the
past five years, BioShield has invested over $20 million in product research
and development, EPA registrations and patent filings and this latest
milestone is another great example of the value that is created with
BioShield's technology foundation."
